Institutional shares held 184 Million
12.8M calls
2.09M puts
Total value of holdings $8.47B
$590M calls
$96.1M puts
Market Cap $6.82B
148,246,000 Shares Out.
Institutional ownership 124.3%
# of Institutions 362


Latest Institutional Activity in BBIO

Top Purchases

Q2 2025
Diversified Trust CO Shares Held: 38.6K ($1.78M)
Q2 2025
Nbc Securities, Inc. Shares Held: 3.3K ($152K)
Q2 2025
First Bank & Trust Shares Held: 8.82K ($406K)
Q2 2025
Parallel Advisors, LLC Shares Held: 131 ($6.02K)
Q1 2025
Janus Henderson Group PLC Shares Held: 7.17M ($330M)

Top Sells

Q2 2025
Assenagon Asset Management S.A. Shares Held: 350K ($16.1M)
Q2 2025
Farther Finance Advisors, LLC Shares Held: 210 ($9.66K)
Q2 2025
Massmutual Trust CO Fsb Shares Held: 33 ($1.52K)
Q1 2025
Kohlberg Kravis Roberts & Co. L.P. Shares Held: 19.3M ($886M)
Q1 2025
Viking Global Investors LP Shares Held: 22.1M ($1.01B)

About BBIO

BridgeBio Pharma, Inc. engages in the discovery, development, and delivery of various medicines for genetic diseases. The company has a pipeline of 30 development programs that include product candidates ranging from early discovery to late-stage development. Its products in development programs include AG10 and BBP-265, a small molecule stabilizer of transthyretin, or TTR that is in Phase 3 clinical trial for the treatment of TTR amyloidosis-cardiomyopathy, or ATTR-CM; BBP-831, a small molecule selective FGFR1-3 inhibitor, which is Phase 2 clinical trial to treat achondroplasia in pediatric patients; and BBP-631, an AAV5 gene transfer product candidate that is in Phase 2 clinical trial for the treatment of congenital adrenal hyperplasia, or CAH, driven by 21-hydroxylase deficiency, or 21OHD. The company also develops Encaleret, a small molecule antagonist of the calcium sensing receptor, or CaSR, which is in phase 2 proof-of-concept clinical trial for Autosomal Dominant Hypocalcemia Type 1, or ADH1; and BBP-711 for the treatment of hyperoxaluria, as well as patients suffering from recurrent kidney stones. In addition, it engages in developing products for Mendelian, oncology, and gene therapy diseases. BridgeBio Pharma, Inc. has license and collaboration agreements with the Leland Stanford Junior University; and The Regents of the University of California; Leidos Biomedical Research, Inc. The company was founded in 2015 and is headquartered in Palo Alto, California.


Insider Transactions at BBIO

Insider Transaction List

View all
Date Insider Transaction Ownership Type Shares Traded Value / Price
View All Transactions

Last 12 Months Summary

Buy / Acquisition
5.57M Shares
From 21 Insiders
Grant, award, or other acquisition 287K shares
Exercise of conversion of derivative security 602K shares
Bona fide gift 4.69M shares
Sell / Disposition
30.8M Shares
From 16 Insiders
Open market or private sale 25.8M shares
Bona fide gift 4.75M shares
Payment of exercise price or tax liability 228K shares

Track Institutional and Insider Activities on BBIO

Follow BridgeBio Pharma, Inc. and customize your updates to receive the information that matters most to you.

Institutional Portfolio Updates

Receive a notification when an Institution or Guru buys or sells BBIO shares.

Notify only if

Insider Trading

Get notified when an Bridge Bio Pharma, Inc. insider buys or sells BBIO shares.

Notify only if

News

Receive news related to BridgeBio Pharma, Inc.

Track Activities on BBIO